InMode Wins Major Legal Battle Against Counterfeit Sellers

Court victory leads to asset freeze and removal of counterfeit Morpheus8 devices, as InMode strengthens efforts to protect patient safety and brand authenticity.

InMode Ltd. (NASDAQ: INMD), a global leader in medical aesthetic technology, has achieved a significant legal win in its ongoing fight against counterfeit devices, cementing its commitment to consumer safety and the protection of its intellectual property.

The U.S. District Court for the Central District of California granted InMode a preliminary injunction against unauthorised sellers of counterfeit Morpheus8 devices on e-commerce platform DHGate. The ruling includes a court-ordered freeze on the defendants’ assets and mandates the removal of infringing listings, effectively halting the distribution of fake devices.

Morpheus8, InMode’s flagship radiofrequency microneedling technology, is widely used in both aesthetic and medical practices for non-surgical skin tightening and contouring. The proliferation of counterfeit versions of this device raised serious concerns around patient safety and clinical effectiveness.

InMode CEO Moshe Mizrahy reiterated the company’s strict zero-tolerance approach to counterfeiting. “We are committed to protecting the public and our customers from unauthorised devices that could put them at risk,” he said. “This legal action is one of many steps we are taking to ensure the integrity of our products and the safety of end users.”

To further reassure practitioners and consumers, InMode has launched a Verified Provider Program. This initiative allows certified clinics and professionals to showcase their use of genuine InMode technology, helping patients identify trustworthy providers and avoid potentially harmful counterfeit treatments.

Despite slightly missing its first-quarter revenue estimates, reporting between $77.2 million and $77.5 million against expectations, InMode has maintained its full-year 2025 revenue guidance of $395 million to $405 million. With a market cap approaching $1 billion and stock currently trading near its 52-week low, analysts suggest the company may be undervalued, particularly given its strong IP enforcement and growth potential.

This legal milestone serves as a warning to counterfeiters globally: InMode is prepared to take decisive action to defend its brand, its clients, and the safety of the industry.

Read our latest issue below:

There are 5 ways you can catch up with SPA+CLINIC

Our quarterly print magazine, delivered to your door. Subscribe here.
Our website, which is updated daily with its own completely unique content and breaking news.
Our weekly newsletter – free to your inbox! Subscribe here.
Our digital magazine – click here to view previous issues.
Our social media – see daily updates on our Instagram, Facebook & Linkedin